for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Halozyme Therapeutics, Inc.

HALO.O

Latest Trade

40.91USD

Change

0.50(+1.24%)

Volume

2,102,064

Today's Range

38.81

 - 

41.03

52 Week Range

12.71

 - 

56.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Halozyme Therapeutics Says Pricing Of Private Offering Of $700 Million Of Convertible Senior Notes Due 2027

Feb 24 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HALOZYME THERAPEUTICS, INC. ANNOUNCES PRICING OF PRIVATE OFFERING OF $700 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027.HALOZYME THERAPEUTICS - CONVERTIBLE NOTES WILL PAY INTEREST SEMI-ANNUALLY IN ARREARS AT AN ANNUAL RATE OF 0.25%.HALOZYME- CONVERTIBLE NOTES HAVE AN INITIAL CONVERSION RATE OF 12.9576 SHARES OF CO'S COMMON STOCK PER $1,000 PRINCIPAL AMOUNT OF CONVERTIBLE NOTES.

Halozyme Reports Proposed Offering Of $500 Mln Of Convertible Senior Notes Due 2027

Feb 23 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HALOZYME THERAPEUTICS, INC. ANNOUNCES PROPOSED OFFERING OF $500 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027.HALOZYME THERAPEUTICS - INTENDS TO OFFER, SUBJECT TO MARKET CONDITIONS AND OTHER FACTORS, $500 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027.

Halozyme Reports Fourth Quarter 2020 Results

Feb 23 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HALOZYME REPORTS FOURTH QUARTER 2020 RESULTS AND FULL YEAR 2020 RESULTS.Q4 EARNINGS PER SHARE $0.50.Q4 REVENUE $121.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $120.2 MILLION.SEES FY 2021 GAAP EARNINGS PER SHARE $1.40 TO $1.55.SEES FY 2021 REVENUE $375 MILLION TO $395 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.53 -- REFINITIV IBES DATA.2021 ROYALTIES PROJECTED TO DOUBLE VERSUS 2020 ROYALTIES.PLANS TO REPURCHASE UP TO $125 MILLION IN COMMON STOCK DURING 2021 AS PART OF $550 MILLION THREE-YEAR SHARE REPURCHASE PLAN.FY2021 EARNINGS PER SHARE VIEW $1.70, REVENUE VIEW $400.2 MILLION -- REFINITIV IBES DATA.

Halozyme Raises Full Year 2020 Guidance

Nov 23 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::SEES FY 2020 EARNINGS PER SHARE $0.90 TO $0.95.SEES FY 2020 REVENUE $265 MILLION TO $275 MILLION.RAISING 2020 REVENUE GUIDANCE TO REFLECT INCREMENTAL ANTICIPATED REVENUES.FY2020 EARNINGS PER SHARE VIEW $0.86, REVENUE VIEW $255.1 MILLION -- REFINITIV IBES DATA.

Horizon Therapeutics PLC And Halozyme Therapeutics Inc Enter Global Collaboration And License Agreement For Enhanze Technology

Nov 23 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HORIZON THERAPEUTICS - DEAL GIVES CO EXCLUSIVE ACCESS TO HALOZYME'S ENHANZE DRUG DELIVERY TECHNOLOGY FOR SC FORMULATION OF MEDICINES TARGETING IGF-1R.HORIZON THERAPEUTICS PLC - HORIZON INTENDS TO USE ENHANZE TO DEVELOP A SC FORMULATION OF TEPEZZA INDICATED FOR TREATMENT OF THYROID EYE DISEASE.HORIZON - WILL MAKE UPFRONT PAYMENT OF $30 MILLION TO HALOZYME, OBLIGATED TO POTENTIALLY PAY UP TO $160 MILLION, SUBJECT TO ACHIEVEMENT OF MILESTONES.

Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo For Her2-Positive Breast Cancer

Nov 13 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HALOZYME ANNOUNCES CHMP RECOMMENDS EU APPROVAL OF ROCHE'S PHESGO® (FIXED-DOSE COMBINATION OF PERJETA® AND HERCEPTIN® FOR SUBCUTANEOUS INJECTION) UTILIZING HALOZYME'S ENHANZE® TECHNOLOGY FOR HER2-POSITIVE BREAST CANCER.HALOZYME THERAPEUTICS- BASED ON CHMP RECOMMENDATION, A FINAL DECISION REGARDING APPROVAL OF PHESGO IS EXPECTED FROM EUROPEAN COMMISSION IN NEAR FUTURE.HALOZYME THERAPEUTICS INC - RECOMMENDATION FROM CHMP IS BASED ON RESULTS FROM PIVOTAL PHASE III FEDERICA STUDY, WHICH MET ITS PRIMARY ENDPOINT.HALOZYME THERAPEUTICS INC - U.S. FDA RECENTLY EXPEDITED APPROVAL OF PHESGO FOR TREATMENT OF EARLY AND METASTATIC HER2-POSITIVE BREAST CANCER.

Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance

Nov 2 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HALOZYME REPORTS THIRD QUARTER 2020 RESULTS AND RAISES FULL YEAR 2020 GUIDANCE.Q3 EARNINGS PER SHARE $0.25.Q3 REVENUE $65.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $60.9 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.19 -- REFINITIV IBES DATA.SEES FY 2020 EARNINGS PER SHARE $0.80 TO $0.85.SEES FY 2020 REVENUE $250 MILLION TO $260 MILLION.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $346.7 MILLION AT SEPTEMBER 30.

Halozyme Reports Q2 EPS Of $0.19

Aug 10 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HALOZYME REPORTS SIGNIFICANT RECENT ACHIEVEMENTS AND SECOND QUARTER 2020 RESULTS.Q2 EARNINGS PER SHARE $0.19.Q2 REVENUE $55.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $66.7 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.25 -- REFINITIV IBES DATA.SEES FY 2020 EARNINGS PER SHARE $0.60 TO $0.75.SEES FY 2020 REVENUE $230 MILLION TO $245 MILLION.

Halozyme To Receive $10 Million Milestone Payment From Janssen

June 22 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HALOZYME TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM JANSSEN.HALOZYME THERAPEUTICS -WILL RECEIVE $10 MILLION MILESTONE PAYMENT FROM JANSSEN BIOTECH TRIGGERED UNDER COLLABORATION & LICENSE AGREEMENT BETWEEN TWO COS.

Halozyme To Receive $15 Mln Milestone Payment From Janssen

May 14 (Reuters) - Halozyme Therapeutics Inc <HALO.O>::HALOZYME TO RECEIVE $15 MILLION MILESTONE PAYMENT FROM JANSSEN.HALOZYME THERAPEUTICS - MILESTONE PAYMENT ASSOCIATED WITH FIRST COMMERCIAL SALE IN U.S. OF JANSSEN'S DARZALEX FASPROTM UTILIZING ENHANZE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up